Improving the use of direct oral anticoagulants in atrial fibrillation

European Journal of Internal Medicine

Volumn 24, Issue 4, 2013, Pages 288-294

  Di Minno, Giovanni ^a   Russolillo, Anna ^a   Gambacorta, Carminio ^a   Di Minno, Alessandro ^a   Prisco, Domenico ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Atrial fibrillation; Bleeding tendency; Costs; Direct oral anticoagulants; Ex vivo tests; Long term adherence

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CHARCOAL; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN;

CARDIAC PATIENT; CARDIOVERSION; CORONARY STENT; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG HALF LIFE; HEART ATRIUM FIBRILLATION; HUMAN; INVASIVE PROCEDURE; KIDNEY FAILURE; LIVER FAILURE; MECHANICAL HEART VALVE; OBSERVATIONAL STUDY; RADIOFREQUENCY ABLATION; REVIEW;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; ELECTRIC COUNTERSHOCK; HUMANS; MEDICATION ADHERENCE; PLATELET AGGREGATION INHIBITORS; RISK;

EID: 84878286571     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.01.021     Document Type: Review

References (45)

1. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Eur Heart J 27 2006 1979 2030
2. S. Connolly, J. Pogue, R. Hart, M. Pfeffer, S. Hohnloser, and S. Chrolavicius Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
3. Investigators A, S.J. Connolly, J. Pogue, R.G. Hart, S.H. Hohnloser, and M. Pfeffer Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
4. J.S. Healey, R.G. Hart, J. Pogue, M.A. Pfeffer, S.H. Hohnloser, and R. De Caterina Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) Stroke 39 2008 1482 1486
5. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation Ann Intern Med 146 2007 857 867
6. G.C. Flaker, J.W. Eikelboom, O. Shestakovska, S. Connolly, S. Kaatz, and A. Budaj Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin Stroke 43 2012 3291 3297
7. S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, and S. Golitsyn Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
8. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, L. Wallentin, and Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
9. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347
10. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
11. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
12. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, and M. Moia Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results J Thromb Haemost 10 2012 1979 1987
13. P.M. Mannucci, A. Nobili, and S. Garattini New drugs for thromboprophylaxis in atrial fibrillation Eur. J. Int. Med 23 2012 1 5
14. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, and S.H. Hohnloser 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
15. Dans AL, Connoly S, Brückmann M, Ezekowitz M, Wallentin L, Yang S, et al. Concomitant use of antiplatelet therapy with Dabigatran or Warfarin (a sub-analysis from RE-LY). Presentation at ESC 2011: session 709009 -709010. e-slides available at: http://spo.escardio.org/eslides/view.aspx?eevtid= 48&fp=1161; 2011. [accessed Sept 2011].
16. K.A. Fox, P.G. Steg, K.A. Eagle, S.G. Goodman, F.A. Jr Anderson, and C.B. Granger Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006 JAMA 297 2007 1892 1900
17. P.A. Merlini, K.A. Bauer, L. Oltrona, D. Ardissino, M. Cattaneo, and C. Belli Persistent activation of coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1994 61 68
18. K.A. Fox, O.H. Dabbous, R.J. Goldberg, K.S. Pieper, K.A. Eagle, and F. Van de Werf Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091 1094
19. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 2002 969 974
20. R. Sørensen, M.L. Hansen, S.Z. Abildstrom, A. Hvelplund, C. Andersson, and C. Jørgensen Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
21. J.H. Alexander, R.D. Lopes, S. James, R. Kilaru, Y. He, and P. Mohan Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
22. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
23. G.N. Levine, E.R. Bates, J.C. Blankenship, S.R. Bailey, J.A. Bittl, and B. Cercek 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
24. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
25. M.N. Di Minno, A. Guida, M. Camera, S. Colli, G. Di Minno, and E. Tremoli Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention Ann Med 43 2011 531 544
26. M.N. Di Minno, D. Prisco, A.L. Ruocco, P. Mastronardi, S. Massa, and G. Di Minno Perioperative handling of patients on antiplatelet therapy with need for surgery Intern Emerg Med 4 2009 279 288
27. P. Sié, C.M. Samama, A. Godier, N. Rosencher, A. Steib, and J.V. Llau Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis Arch Cardiovasc Dis 104 2011 669 676
28. J.S. Healey, J. Eikelboom, J. Douketis, L. Wallentin, J. Oldgren, and S. Yang Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY randomized trial Circulation 126 2012 343 348
29. M.V. Huisman, G.Y. Lip, H.C. Diener, M. Brueckmann, J. van Ryn, and A. Clemens Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice Thromb Haemost 107 2012 838 847
30. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, and Palareti Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost 106 2011 868 876
31. A.G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 108 2012 876 886
32. D. Lakkireddy, Y.M. Reddy, L. Di Biase, S.R. Vanga, P. Santangeli, and V. Swarup Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. Results from a multicenter prospective registry J Am Coll Cardiol 59 2012 1168 1174
33. R.A. Winkle, R.H. Mead, G. Engel, M.H. Kong, and R.A. Patrawala The use of dabigatran immediately after atrial fibrillation ablation J Cardiovasc Electrophysiol 23 2012 264 268
34. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, S. Yang, M. Chernick, and T.H. Aikens Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
35. K. Huber, K.J. Airaksinen, T. Cuisset, F. Marin, A. Rubboli, and G.Y. Lip Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: page 26 of 29 ESC guidelines similarities and dissimilarities between North America and Europe Thromb Haemost 106 2011 569 571
36. M.D. Ezekowitz, L. Wallentin, S.J. Connolly, A. Parekh, M.R. Chernick, and J. Pogue Dabigatran and warfarin in vitamin K antagonist-naïve and -experienced cohorts with atrial fibrillation Circulation 122 2010 2246 2253
37. J. van Ryn, J. Stangier, S. Haertter, K.-H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
38. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
39. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J.L. Crackowski, and G. Pernod Effect of nonspecific reversal agents on anticoagulant activity of dabigatran, rivaroxaban. A randomised crossover ex vivo study in healthy volunteers Thromb Haemost 108 2012 217 224
40. A. Majeed, A. Eelde, A. Agren, S. Schulman, and M. Holmström Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy Thromb Res 129 2012 146 151
41. M.N. Diringer, B.E. Skolnick, S.A. Mayer, T. Steiner, S.M. Davis, and N.C. Brun Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial Stroke 41 2010 48 53
42. S.H. Hohnloser, Z. Hijazi, L. Thoms, J.H. Alexander, J. Amerena, and M. Hanna Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
43. A. Tripodi Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Thromb Haemost 105 2011 735 736
44. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogne Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb Haemost 107 2012 985 997
45. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, H. Yang, J. Ansell, and M.C. Bahit Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial Lancet 380 2012 1749 1758